27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
AC-1202 was compared to Placebo in several population groups, including: intention-to-treat (ITT), per protocol, and dosage compliant groups. 5 key findings →
Participants: 55 Evidence: high
Full summary, score breakdown and related studies → Original source
These data suggest that beta-HCH is associated with a diagnosis of PD. 4 key findings →
Design: case-control study Participants: 20 Evidence: moderate
Full summary, score breakdown and related studies → Original source
PIB-positive subjects with mild cognitive impairment (MCI) are significantly more likely to convert to AD than PIB-negative patients, faster converters having higher PIB retention levels at baseline than slower converters. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Treatment success in Alzheimer disease (AD) trials is generally based on benefits over placebo-treated controls. 2 key findings →
Participants: 3,403 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
During follow-up, 203 cases of hospitalisation with dementia were identified. 5 key findings →
Participants: 151 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Patients with dementia were older and had higher rates of hypertension, coronary artery disease, renal failure, heart failure, and prior strokes. 5 key findings →
Participants: 37,025 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Attention to the role of n-3 long-chain fatty acids in human health and disease has been continuously increased during recent decades. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Neuronal accumulation of alpha-synuclein and Lewy body formation are characteristic to many neurodegenerative diseases, including Parkinson's disease (PD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Although senile plaques focally disrupt neuronal health, the functional response of astrocytes to Alzheimer's disease pathology is unknown. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Full summary, score breakdown and related studies → Original source Free full text
The brain changes associated with AD may already begin developing early in middle age, especially among APOE epsilon 4 carriers. 5 key findings →
Participants: 603 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Rivastigmine therapy for PDD is associated with significant tradeoffs in efficacy and adverse effects. 5 key findings →
Design: randomized controlled trial Participants: 541 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In recent years, a series of publications have demonstrated a potentially important role for magnetic resonance imaging in the pre-mortem diagnosis of sporadic Creutzfeldt-Jakob disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our study estimates the sensitivity and specificity of Medicare claims to identify clinically-diagnosed dementia, and documents how errors in dementia assessment affect dementia cost estimates. 4 key findings →
Participants: 758 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
MRI evidence of small subacute infarcts is present in a substantial proportion of living patients with advanced cerebral amyloid angiopathy (CAA). 4 key findings →
Participants: 78 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Future research should examine both current and pre-caregiving relationship quality. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Community-based cohorts of older persons may differ neuropathologically from clinic-based cohorts. 4 key findings →
Participants: 386 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Apathy is a persistent behavioural feature in PD with a high incidence and prevalence over time. 3 key findings →
Design: longitudinal study Participants: 139 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The dopamine hypothesis of schizophrenia has been one of the most enduring ideas in psychiatry. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Inclusions of TAR DNA-binding protein-43 (TDP-43), a nuclear protein that regulates transcription and RNA splicing, are the defining histopathological feature of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-Us) and sporadic and familial forms of amyotrophic lateral sclerosis (ALS). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Greater fish and omega-3 (n-3) polyunsaturated fatty acid (PUFA) intake may reduce dementia risk; however, previous studies have reported conflicting results, which were largely based on short-term follow-up. 4 key findings →
Participants: 5,395 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The role of microglial cells in the pathogenesis of Alzheimer's disease (AD) neurodegeneration is unknown. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In the past 10 years, there has been a virtual explosion in the literature concerning the construct of mild cognitive impairment.
Full summary, score breakdown and related studies → Original source Free full text
HCPs of NH patients with advanced dementia can most commonly expect to encounter medical decisions relating to feeding problems, infections, and pain. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The in vivo measure of cerebral amyloidosis known as [(11)C]PiB is associated with cross-sectional regionally specific brain atrophy and longitudinal cognitive decline in multiple cognitive domains that occur before the clinical diagnosis of Alzheimer disease. 4 key findings →
Design: cross-sectional Participants: 135 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →